Bioventus Inc. - BVS STOCK NEWS

Bioventus Inc. (Nasdaq: BVS) has acquired Misonix, Inc., enhancing its position in regenerative medicine and surgical applications. Misonix stockholders can choose $28 in cash or 1.6839 shares of Bioventus stock per share held. This strategic acquisition targets a $15 billion market, aiming for double-digit revenue growth. The integration is expected to broaden Bioventus' commercial reach, leveraging its extensive sales force in areas like spinal surgery and wound treatment. Key leadership from Misonix will join Bioventus' board, indicating a commitment to shared growth.

Bioventus (Nasdaq: BVS) will release its third quarter fiscal year 2021 financial results on November 9, 2021, before market opening. The company will host a conference call at 8:30 a.m. ET to discuss these results and offer a business update. Participants can join by dialing 844-945-2085, with an international dial-in option available. A live webcast will also be accessible on the company's investor relations website and will be archived for future reference until November 9, 2022.

Bioventus (Nasdaq: BVS) has received stockholder approval for its acquisition of Misonix (Nasdaq: MSON), expected to close by October 29, 2021. This merger was initially announced on July 29, 2021, under which Misonix stockholders will receive either 1.6839 shares of Bioventus stock or $28 in cash for each share of Misonix. The deal represents a 25% premium based on Misonix's 30-day VWAP prior to the agreement. Following the merger, Misonix will become a wholly-owned subsidiary of Bioventus, enhancing their global pain treatment and restorative therapy portfolio.

Bioventus (Nasdaq: BVS) and Misonix (Nasdaq: MSON) announced an election deadline of October 25, 2021, for Misonix stockholders to choose their preferred merger consideration in the proposed acquisition. Each Misonix share will convert to either 1.6839 shares of Bioventus Class A stock or $28.00 in cash, with the option for hybrid election. Record holders must return their Letter of Election and Transmittal to the Exchange Agent by the deadline. A special meeting for stockholders to vote on the merger is set for October 26, 2021. This merger is expected to enhance Bioventus’ product offerings.

Bioventus (Nasdaq: BVS) announced that the American Academy of Orthopaedic Surgeons (AAOS) has released updated clinical practice guidelines (CPG) endorsing the use of high molecular weight cross-linked hyaluronic acid treatments, including DUROLANE, for knee osteoarthritis (OA). The guidelines highlight the effectiveness of these treatments for patients with low to moderate OA who have not responded to other therapies. DUROLANE is noted for its significant pain relief benefits and safety profile. The recommendations are aligned with Bioventus’s clinical practices.

Bioventus (Nasdaq: BVS) announced a $50 million escrow payment as part of its acquisition process for CartiHeal Ltd., indicating strong intent to advance this deal. This decision follows a thorough review of clinical data for the Agili-C implant, which has received FDA's Breakthrough Device Designation. Agili-C aims to treat cartilage defects in the knee, presenting a market opportunity for up to 650,000 patients annually. Bioventus will collaborate with CartiHeal ahead of potential FDA approval to prepare for commercialization efforts.

Bioventus Inc. (Nasdaq: BVS) has announced a strategic investment in Trice Medical, securing exclusive sales and distribution rights for Trice’s products outside the US. This investment includes a co-development agreement to integrate Trice’s technologies with Bioventus’ peripheral nerve stimulation offerings, enhancing product adoption. Trice, known for its innovative surgical devices, aims to improve patient recovery and reduce costs. This alliance aligns with Bioventus' strategy to expand its portfolio in the sports medicine and orthopedic sectors.

Bioventus (Nasdaq: BVS) has appointed Dave Crawford as Vice President, Investor Relations and Treasurer, bringing over 20 years of finance experience to the role. Previously with Avanos Medical, Crawford has a strong background in finance and treasury from Kimberly-Clark and Eli Lilly. His MBA is from Duke University, and he holds a Bachelor’s in Accounting from Notre Dame. The company continues to focus on delivering clinically proven, cost-effective products for healing.

SV Health Investors, a global healthcare investment firm, announced significant realizations from its growth equity portfolio. HillRom acquired Bardy Diagnostics on August 6, enhancing its ambulatory cardiac monitoring services. Healthify agreed to be acquired by WellSky, focusing on integrating social services into healthcare. Additionally, Bioventus announced a cash and stock deal to acquire Misonix, a company supported by SV since 2017. SV's initiatives align with its strategy of driving growth and enhancing patient access while managing $2.6B in assets.